<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">26886206</PMID>
      <DateCompleted>
        <Year>2017</Year>
        <Month>04</Month>
        <Day>11</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2018</Year>
        <Month>11</Month>
        <Day>13</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1432-1459</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>263</Volume>
            <Issue>8</Issue>
            <PubDate>
              <Year>2016</Year>
              <Month>Aug</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of neurology</Title>
          <ISOAbbreviation>J Neurol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society.</ArticleTitle>
        <Pagination>
          <StartPage>1473</StartPage>
          <EndPage>1494</EndPage>
          <MedlinePgn>1473-94</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00415-016-8045-z</ELocationID>
        <Abstract>
          <AbstractText>Myasthenia gravis (MG) is an autoimmune antibody-mediated disorder of neuromuscular synaptic transmission. The clinical hallmark of MG consists of fluctuating fatigability and weakness affecting ocular, bulbar and (proximal) limb skeletal muscle groups. MG may either occur as an autoimmune disease with distinct immunogenetic characteristics or as a paraneoplastic syndrome associated with tumors of the thymus. Impairment of central thymic and peripheral self-tolerance mechanisms in both cases is thought to favor an autoimmune CD4(+) T cell-mediated B cell activation and synthesis of pathogenic high-affinity autoantibodies of either the IgG1 and 3 or IgG4 subclass. These autoantibodies bind to the nicotinic acetylcholine receptor (AchR) itself, or muscle-specific tyrosine-kinase (MuSK), lipoprotein receptor-related protein 4 (LRP4) and agrin involved in clustering of AchRs within the postsynaptic membrane and structural maintenance of the neuromuscular synapse. This results in disturbance of neuromuscular transmission and thus clinical manifestation of the disease. Emphasizing evidence from clinical trials, we provide an updated overview on immunopathogenesis, and derived current and future treatment strategies for MG divided into: (a) symptomatic treatments facilitating neuromuscular transmission, (b) antibody-depleting treatments, and</AbstractText>
          <CopyrightInformation>(c) immunotherapeutic treatment strategies.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Melzer</LastName>
            <ForeName>Nico</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, University of Münster, Albert-Schweitzer-Campus 1, 48149, Münster, Germany. nico.melzer@ukmuenster.de.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ruck</LastName>
            <ForeName>Tobias</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, University of Münster, Albert-Schweitzer-Campus 1, 48149, Münster, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fuhr</LastName>
            <ForeName>Peter</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, University of Basel, Basel, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gold</LastName>
            <ForeName>Ralf</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, University of Bochum, Bochum, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hohlfeld</LastName>
            <ForeName>Reinhard</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Clinical Neuroimmunology, Ludwig-Maximilians-University Munich, Munich, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Marx</LastName>
            <ForeName>Alexander</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Pathology, University Medical Centre Mannheim, University of Heidelberg, Mannheim, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Melms</LastName>
            <ForeName>Arthur</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, University of Erlangen, Erlangen, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tackenberg</LastName>
            <ForeName>Björn</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, University of Marburg, Marburg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Schalke</LastName>
            <ForeName>Berthold</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, University of Regensburg, Regensburg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Schneider-Gold</LastName>
            <ForeName>Christiane</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, University of Bochum, Bochum, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zimprich</LastName>
            <ForeName>Fritz</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Medical University of Vienna, Vienna, Austria.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Meuth</LastName>
            <ForeName>Sven G</ForeName>
            <Initials>SG</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, University of Münster, Albert-Schweitzer-Campus 1, 48149, Münster, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wiendl</LastName>
            <ForeName>Heinz</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, University of Münster, Albert-Schweitzer-Campus 1, 48149, Münster, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2016</Year>
          <Month>02</Month>
          <Day>17</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Neurol</MedlineTA>
        <NlmUniqueID>0423161</NlmUniqueID>
        <ISSNLinking>0340-5354</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D019468" MajorTopicYN="Y">Disease Management</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005858" MajorTopicYN="N">Germany</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009157" MajorTopicYN="Y">Myasthenia Gravis</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012955" MajorTopicYN="N">Societies, Medical</DescriptorName>
          <QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Myasthenia gravis</Keyword>
        <Keyword MajorTopicYN="N">Pathogenesis</Keyword>
        <Keyword MajorTopicYN="N">Treatment guidelines</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2015</Year>
          <Month>12</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2016</Year>
          <Month>1</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2016</Year>
          <Month>1</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2016</Year>
          <Month>2</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2016</Year>
          <Month>2</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2017</Year>
          <Month>4</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">26886206</ArticleId>
        <ArticleId IdType="pmc">PMC4971048</ArticleId>
        <ArticleId IdType="doi">10.1007/s00415-016-8045-z</ArticleId>
        <ArticleId IdType="pii">10.1007/s00415-016-8045-z</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Albuquerque EX, Pereira EF, Alkondon M, Rogers SW. Mammalian nicotinic acetylcholine receptors: from structure to function. Physiol Rev. 2009;89:73–120. doi: 10.1152/physrev.00015.2008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1152/physrev.00015.2008</ArticleId>
            <ArticleId IdType="pmc">PMC2713585</ArticleId>
            <ArticleId IdType="pubmed">19126755</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arsura E, Brunner NG, Namba T, Grob D. High-dose intravenous methylprednisolone in myasthenia gravis. Arch Neurol. 1985;42:1149–1153. doi: 10.1001/archneur.1985.04060110031011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archneur.1985.04060110031011</ArticleId>
            <ArticleId IdType="pubmed">4062612</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aschenbrenner K, D’Cruz LM, Vollmann EH, Hinterberger M, Emmerich J, Swee LK, Rolink A, Klein L. Selection of Foxp3+ regulatory T cells specific for self antigen expressed and presented by Aire + medullary thymic epithelial cells. Nat Immunol. 2007;8:351–358. doi: 10.1038/ni1444.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ni1444</ArticleId>
            <ArticleId IdType="pubmed">17322887</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ashraf VV, Taly AB, Veerendrakumar M, Rao S. Myasthenia gravis in children: a longitudinal study. Acta Neurol Scand. 2006;114:119–123. doi: 10.1111/j.1600-0404.2006.00646.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1600-0404.2006.00646.x</ArticleId>
            <ArticleId IdType="pubmed">16867035</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bachmann K, Burkhardt D, Schreiter I, Kaifi J, Busch C, Thayssen G, Izbicki JR, Strate T. Long-term outcome and quality of life after open and thoracoscopic thymectomy for myasthenia gravis: analysis of 131 patients. Surg Endosc. 2008;22:2470–2477. doi: 10.1007/s00464-008-9794-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00464-008-9794-2</ArticleId>
            <ArticleId IdType="pubmed">18297352</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bae JS, Go SM, Kim BJ. Clinical predictors of steroid-induced exacerbation in myasthenia gravis. J Clin Neurosci. 2006;13:1006–1010. doi: 10.1016/j.jocn.2005.12.041.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jocn.2005.12.041</ArticleId>
            <ArticleId IdType="pubmed">17074487</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bain PG, Motomura M, Newsom-Davis J, Misbah SA, Chapel HM, Lee ML, Vincent A, Lang B. Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Neurology. 1996;47:678–683. doi: 10.1212/WNL.47.3.678.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.47.3.678</ArticleId>
            <ArticleId IdType="pubmed">8797464</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Balandina A, Lecart S, Dartevelle P, Saoudi A, Berrih-Aknin S. Functional defect of regulatory CD4(+)CD25+ T cells in the thymus of patients with autoimmune myasthenia gravis. Blood. 2005;105:735–741. doi: 10.1182/blood-2003-11-3900.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2003-11-3900</ArticleId>
            <ArticleId IdType="pmc">PMC1847365</ArticleId>
            <ArticleId IdType="pubmed">15454488</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barik A, Lu Y, Sathyamurthy A, Bowman A, Shen C, Li L, Xiong WC, Mei L. LRP4 is critical for neuromuscular junction maintenance. J Neurosci. 2014;34:13892–13905. doi: 10.1523/JNEUROSCI.1733-14.2014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.1733-14.2014</ArticleId>
            <ArticleId IdType="pmc">PMC4198535</ArticleId>
            <ArticleId IdType="pubmed">25319686</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barth D, Nabavi Nouri M, Ng E, Nwe P, Bril V. Comparison of IVIg and PLEX in patients with myasthenia gravis. Neurology. 2011;76:2017–2023. doi: 10.1212/WNL.0b013e31821e5505.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0b013e31821e5505</ArticleId>
            <ArticleId IdType="pmc">PMC3109880</ArticleId>
            <ArticleId IdType="pubmed">21562253</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Benatar M, Kaminski H. Medical and surgical treatment for ocular myasthenia. Cochrane Database Syst Rev. 2012;12:CD005081.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6485481</ArticleId>
            <ArticleId IdType="pubmed">23235620</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Birmingham UoAa (2006) Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone Therapy. ClinicalTrialsgov NCT00294658</Citation>
        </Reference>
        <Reference>
          <Citation>Bromberg MB, Wald JJ, Forshew DA, Feldman EL, Albers JW. Randomized trial of azathioprine or prednisone for initial immunosuppressive treatment of myasthenia gravis. J Neurol Sci. 1997;150:59–62. doi: 10.1016/S0022-510X(97)05370-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0022-510X(97)05370-7</ArticleId>
            <ArticleId IdType="pubmed">9260858</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Buckley C, Douek D, Newsom-Davis J, Vincent A, Willcox N. Mature, long-lived CD4+ and CD8+ T cells are generated by the thymoma in myasthenia gravis. Ann Neurol. 2001;50:64–72. doi: 10.1002/ana.1017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.1017</ArticleId>
            <ArticleId IdType="pubmed">11456312</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carr AS, Cardwell CR, McCarron PO, McConville J. A systematic review of population based epidemiological studies in Myasthenia Gravis. BMC Neurol. 2010;10:46. doi: 10.1186/1471-2377-10-46.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1471-2377-10-46</ArticleId>
            <ArticleId IdType="pmc">PMC2905354</ArticleId>
            <ArticleId IdType="pubmed">20565885</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Castro D, Derisavifard S, Anderson M, Greene M, Iannaccone S. Juvenile myasthenia gravis: a twenty-year experience. J Clin Neuromuscul Dis. 2013;14:95–102. doi: 10.1097/CND.0b013e318253a48e.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/CND.0b013e318253a48e</ArticleId>
            <ArticleId IdType="pubmed">23492460</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cavalcante P, Bernasconi P, Mantegazza R. Autoimmune mechanisms in myasthenia gravis. Curr Opin Neurol. 2012;25:621–629. doi: 10.1097/WCO.0b013e328357a829.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/WCO.0b013e328357a829</ArticleId>
            <ArticleId IdType="pubmed">22941261</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cea G, Benatar M, Verdugo RJ, Salinas RA. Thymectomy for non-thymomatous myasthenia gravis. Cochrane Database Syst Rev. 2013;10:CD008111.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24122674</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chan A, Lee DH, Linker R, Mohr A, Toyka KV, Gold R. Rescue therapy with anti-CD20 treatment in neuroimmunologic breakthrough disease. J Neurol. 2007;254:1604–1606. doi: 10.1007/s00415-007-0593-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00415-007-0593-9</ArticleId>
            <ArticleId IdType="pubmed">17713826</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chuang WY, Strobel P, Bohlender-Willke AL, Rieckmann P, Nix W, Schalke B, Gold R, Opitz A, Klinker E, Inoue M, Muller-Hermelink HK, Saruhan-Direskeneli G, Bugert P, Willcox N, Marx A. Late-onset myasthenia gravis—CTLA4(low) genotype association and low-for-age thymic output of naive T cells. J Autoimmun. 2014;52:122–129. doi: 10.1016/j.jaut.2013.12.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaut.2013.12.006</ArticleId>
            <ArticleId IdType="pubmed">24373506</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ciafaloni E, Massey JM, Tucker-Lipscomb B, Sanders DB. Mycophenolate mofetil for myasthenia gravis: an open-label pilot study. Neurology. 2001;56:97–99. doi: 10.1212/WNL.56.1.97.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.56.1.97</ArticleId>
            <ArticleId IdType="pubmed">11148243</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Fisher E, Brinar VV, Giovannoni G, Stojanovic M, Ertik BI, Lake SL, Margolin DH, Panzara MA, Compston DA. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet. 2012;380:1819–1828. doi: 10.1016/S0140-6736(12)61769-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(12)61769-3</ArticleId>
            <ArticleId IdType="pubmed">23122652</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cole RN, Reddel SW, Gervasio OL, Phillips WD. Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction. Ann Neurol. 2008;63:782–789. doi: 10.1002/ana.21371.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.21371</ArticleId>
            <ArticleId IdType="pubmed">18384168</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012;380:1829–1839. doi: 10.1016/S0140-6736(12)61768-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(12)61768-1</ArticleId>
            <ArticleId IdType="pubmed">23122650</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Confavreux C, Saddier P, Grimaud J, Moreau T, Adeleine P, Aimard G. Risk of cancer from azathioprine therapy in multiple sclerosis: a case-control study. Neurology. 1996;46:1607–1612. doi: 10.1212/WNL.46.6.1607.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.46.6.1607</ArticleId>
            <ArticleId IdType="pubmed">8649558</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cortese I, Chaudhry V, So YT, Cantor F, Cornblath DR, Rae-Grant A. Evidence-based guideline update: plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2011;76:294–300. doi: 10.1212/WNL.0b013e318207b1f6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0b013e318207b1f6</ArticleId>
            <ArticleId IdType="pmc">PMC3034395</ArticleId>
            <ArticleId IdType="pubmed">21242498</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Costa J, Evangelista T, Conceicao I, de Carvalho M. Repetitive nerve stimulation in myasthenia gravis–relative sensitivity of different muscles. Clin Neurophysiol. 2004;115:2776–2782. doi: 10.1016/j.clinph.2004.05.024.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.clinph.2004.05.024</ArticleId>
            <ArticleId IdType="pubmed">15546785</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Curnow J, Corlett L, Willcox N, Vincent A. Presentation by myoblasts of an epitope from endogenous acetylcholine receptor indicates a potential role in the spreading of the immune response. J Neuroimmunol. 2001;115:127–134. doi: 10.1016/S0165-5728(01)00272-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0165-5728(01)00272-7</ArticleId>
            <ArticleId IdType="pubmed">11282162</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dardenne M, Savino W, Bach JF. Thymomatous epithelial cells and skeletal muscle share a common epitope defined by a monoclonal antibody. Am J Pathol. 1987;126:194–198.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1899544</ArticleId>
            <ArticleId IdType="pubmed">2433946</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dau PC, Lindstrom JM, Cassel CK, Denys EH, Shev EE, Spitler LE. Plasmapheresis and immunosuppressive drug therapy in myasthenia gravis. N Engl J Med. 1977;297:1134–1140. doi: 10.1056/NEJM197711242972102.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJM197711242972102</ArticleId>
            <ArticleId IdType="pubmed">917042</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Feo LG, Schottlender J, Martelli NA, Molfino NA. Use of intravenous pulsed cyclophosphamide in severe, generalized myasthenia gravis. Muscle Nerve. 2002;26:31–36. doi: 10.1002/mus.10133.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mus.10133</ArticleId>
            <ArticleId IdType="pubmed">12115946</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diaz-Manera J, Martinez-Hernandez E, Querol L, Klooster R, Rojas-Garcia R, Suarez-Calvet X, Munoz-Blanco JL, Mazia C, Straasheijm KR, Gallardo E, Juarez C, Verschuuren JJ, Illa I. Long-lasting treatment effect of rituximab in MuSK myasthenia. Neurology. 2012;78:189–193. doi: 10.1212/WNL.0b013e3182407982.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0b013e3182407982</ArticleId>
            <ArticleId IdType="pubmed">22218276</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diaz-Manera J, Rojas-Garcia R, Gallardo E, Juarez C, Martinez-Domeno A, Martinez-Ramirez S, Dalmau J, Blesa R, Illa I. Antibodies to AChR, MuSK and VGKC in a patient with myasthenia gravis and Morvan’s syndrome. Nat Clin Pract Neurol. 2007;3:405–410. doi: 10.1038/ncpneuro0526.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncpneuro0526</ArticleId>
            <ArticleId IdType="pubmed">17611489</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Douek DC, McFarland RD, Keiser PH, Gage EA, Massey JM, Haynes BF, Polis MA, Haase AT, Feinberg MB, Sullivan JL, Jamieson BD, Zack JA, Picker LJ, Koup RA. Changes in thymic function with age and during the treatment of HIV infection. Nature. 1998;396:690–695. doi: 10.1038/25374.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/25374</ArticleId>
            <ArticleId IdType="pubmed">9872319</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Drachman DB, Adams RN, Hu R, Jones RJ, Brodsky RA. Rebooting the immune system with high-dose cyclophosphamide for treatment of refractory myasthenia gravis. Ann NY Acad Sci. 2008;1132:305–314. doi: 10.1196/annals.1405.033.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1196/annals.1405.033</ArticleId>
            <ArticleId IdType="pmc">PMC3390145</ArticleId>
            <ArticleId IdType="pubmed">18567882</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Drachman DB, Jones RJ, Brodsky RA. Treatment of refractory myasthenia: “rebooting” with high-dose cyclophosphamide. Ann Neurol. 2003;53:29–34. doi: 10.1002/ana.10400.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.10400</ArticleId>
            <ArticleId IdType="pubmed">12509845</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dudel J, Birnberger KL, Toyka KV, Schlegel C, Besinger U. Effects of myasthenic immunoglobulins and of prednisolone on spontaneous miniature end-plate potentials in mouse diaphragms. Exp Neurol. 1979;66:365–380. doi: 10.1016/0014-4886(79)90087-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0014-4886(79)90087-6</ArticleId>
            <ArticleId IdType="pubmed">226390</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eienbroker C, Seitz F, Spengler A, Kurz H, Seipelt M, Sommer N, Oertel WH, Timmesfeld N, Tackenberg B (2014) IVIg maintenance treatment in myasthenia gravis—a RCT sample size simulation. Muscle Nerve</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24710856</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Evoli A, Batocchi AP, Minisci C, Di Schino C, Tonali P. Clinical characteristics and prognosis of myasthenia gravis in older people. J Am Geriatr Soc. 2000;48:1442–1448. doi: 10.1111/j.1532-5415.2000.tb02635.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1532-5415.2000.tb02635.x</ArticleId>
            <ArticleId IdType="pubmed">11083321</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Evoli A, Bianchi MR, Riso R, Minicuci GM, Batocchi AP, Servidei S, Scuderi F, Bartoccioni E. Response to therapy in myasthenia gravis with anti-MuSK antibodies. Ann NY Acad Sci. 2008;1132:76–83. doi: 10.1196/annals.1405.012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1196/annals.1405.012</ArticleId>
            <ArticleId IdType="pubmed">18567856</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Evoli A, Di Schino C, Marsili F, Punzi C. Successful treatment of myasthenia gravis with tacrolimus. Muscle Nerve. 2002;25:111–114. doi: 10.1002/mus.10018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mus.10018</ArticleId>
            <ArticleId IdType="pubmed">11754194</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Evoli A, Tonali PA, Padua L, Monaco ML, Scuderi F, Batocchi AP, Marino M, Bartoccioni E. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain. 2003;126:2304–2311. doi: 10.1093/brain/awg223.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/awg223</ArticleId>
            <ArticleId IdType="pubmed">12821509</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Finn R, Coates PM. Plasma exchange in myasthenia gravis. Lancet. 1977;1:190–191. doi: 10.1016/S0140-6736(77)91782-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(77)91782-2</ArticleId>
            <ArticleId IdType="pubmed">64714</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fuhr P, Gold R, Hohlfeld R, Melms A, Melzer N, Tackenberg B, Schalke B, Schneider-Gold C, Wiendl H, Zimprich F (2014) Diagnostik und Therapie der Myasthenia gravis und des Lambert-Eaton-Syndroms. Leitlinien der Deutschen Gesellschaft für Neurologie</Citation>
        </Reference>
        <Reference>
          <Citation>Gadient P, Bolton J, Puri V. Juvenile myasthenia gravis: three case reports and a literature review. J Child Neurol. 2009;24:584–590. doi: 10.1177/0883073808325651.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/0883073808325651</ArticleId>
            <ArticleId IdType="pubmed">19406758</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group. Ann Neurol. 1997;41:789–796. doi: 10.1002/ana.410410615.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.410410615</ArticleId>
            <ArticleId IdType="pubmed">9189040</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gajdos P, Chevret S, Toyka K (2008) Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev CD002277</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18254004</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gajdos P, Chevret S, Toyka K (2002) Plasma exchange for myasthenia gravis. Cochrane Database Syst Rev CD002275</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12519572</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gajdos P, Chevret S, Toyka KV. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev. 2012;12:CD002277.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7133495</ArticleId>
            <ArticleId IdType="pubmed">23235588</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gajdos P, Tranchant C, Clair B, Bolgert F, Eymard B, Stojkovic T, Attarian S, Chevret S, Myasthenia Gravis Clinical Study G  Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin: a randomized double-blind clinical trial. Arch Neurol. 2005;62:1689–1693. doi: 10.1001/archneur.62.11.1689.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archneur.62.11.1689</ArticleId>
            <ArticleId IdType="pubmed">16286541</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gasperi C, Melms A, Schoser B, Zhang Y, Meltoranta J, Risson V, Schaeffer L, Schalke B, Kroger S. Anti-agrin autoantibodies in myasthenia gravis. Neurology. 2014;82:1976–1983. doi: 10.1212/WNL.0000000000000478.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000000478</ArticleId>
            <ArticleId IdType="pubmed">24793185</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gelfand EW. Intravenous immune globulin in autoimmune and inflammatory diseases. N Engl J Med. 2012;367:2015–2025. doi: 10.1056/NEJMra1009433.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMra1009433</ArticleId>
            <ArticleId IdType="pubmed">23171098</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gellert K, Bottger J, Martin T, Werner J, Mangler C, Martin H. Thoracoscopic thymectomy in the treatment concept for myasthenia gravis. Surg Technol Int. 2005;14:99–104.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16525960</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giovannoni G, Gold R, Selmaj K, Havrdova E, Montalban X, Radue EW, Stefoski D, McNeill M, Amaravadi L, Sweetser M, Elkins J, O’Neill G. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial. Lancet Neurol. 2014;13:472–481. doi: 10.1016/S1474-4422(14)70039-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(14)70039-0</ArticleId>
            <ArticleId IdType="pubmed">24656609</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giraud M, Taubert R, Vandiedonck C, Ke X, Levi-Strauss M, Pagani F, Baralle FE, Eymard B, Tranchant C, Gajdos P, Vincent A, Willcox N, Beeson D, Kyewski B, Garchon HJ. An IRF8-binding promoter variant and AIRE control CHRNA1 promiscuous expression in thymus. Nature. 2007;448:934–937. doi: 10.1038/nature06066.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature06066</ArticleId>
            <ArticleId IdType="pubmed">17687331</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gisbert JP, Gomollon F, Cara C, Luna M, Gonzalez-Lama Y, Pajares JM, Mate J, Guijarro LG. Thiopurine methyltransferase activity in Spain: a study of 14,545 patients. Dig Dis Sci. 2007;52:1262–1269. doi: 10.1007/s10620-006-9119-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10620-006-9119-z</ArticleId>
            <ArticleId IdType="pubmed">17334911</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gladstone DE, Brannagan TH, 3rd, Schwartzman RJ, Prestrud AA, Brodsky I. High dose cyclophosphamide for severe refractory myasthenia gravis. J Neurol Neurosurg Psychiatry. 2004;75:789–791. doi: 10.1136/jnnp.2003.019232.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp.2003.019232</ArticleId>
            <ArticleId IdType="pmc">PMC1763586</ArticleId>
            <ArticleId IdType="pubmed">15090586</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gold R, Giovannoni G, Selmaj K, Havrdova E, Montalban X, Radue EW, Stefoski D, Robinson R, Riester K, Rana J, Elkins J, O’Neill G. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet. 2013;381:2167–2175. doi: 10.1016/S0140-6736(12)62190-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(12)62190-4</ArticleId>
            <ArticleId IdType="pubmed">23562009</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goldstein G, Whittingham S. Experimental autoimmune thymitis. An animal model of human myasthenia gravis. Lancet. 1966;2:315–318. doi: 10.1016/S0140-6736(66)92599-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(66)92599-2</ArticleId>
            <ArticleId IdType="pubmed">4161495</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gregersen PK, Kosoy R, Lee AT, Lamb J, Sussman J, McKee D, Simpfendorfer KR, Pirskanen-Matell R, Piehl F, Pan-Hammarstrom Q, Verschuuren JJ, Titulaer MJ, Niks EH, Marx A, Strobel P, Tackenberg B, Putz M, Maniaol A, Elsais A, Tallaksen C, Harbo HF, Lie BA, Raychaudhuri S, de Bakker PI, Melms A, Garchon HJ, Willcox N, Hammarstrom L, Seldin MF. Risk for myasthenia gravis maps to a (151) Pro– &gt; Ala change in TNIP1 and to human leukocyte antigen-B*08. Ann Neurol. 2012;72:927–935. doi: 10.1002/ana.23691.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.23691</ArticleId>
            <ArticleId IdType="pmc">PMC3535539</ArticleId>
            <ArticleId IdType="pubmed">23055271</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gronseth GS, Barohn RJ. Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000;55:7–15. doi: 10.1212/WNL.55.1.7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.55.1.7</ArticleId>
            <ArticleId IdType="pubmed">10891896</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guillermo GR, Tellez-Zenteno JF, Weder-Cisneros N, Mimenza A, Estanol B, Remes-Troche JM, Cantu-Brito C. Response of thymectomy: clinical and pathological characteristics among seronegative and seropositive myasthenia gravis patients. Acta Neurol Scand. 2004;109:217–221. doi: 10.1034/j.1600-0404.2003.00209.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1034/j.1600-0404.2003.00209.x</ArticleId>
            <ArticleId IdType="pubmed">14763961</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guptill JT, Sanders DB, Evoli A. Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts. Muscle Nerve. 2011;44:36–40. doi: 10.1002/mus.22006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mus.22006</ArticleId>
            <ArticleId IdType="pubmed">21674519</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hanisch F, Wendt M, Zierz S. Mycophenolate mofetil as second line immunosuppressant in Myasthenia gravis–a long-term prospective open-label study. Eur J Med Res. 2009;14:364–366. doi: 10.1186/2047-783X-14-8-364.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/2047-783X-14-8-364</ArticleId>
            <ArticleId IdType="pmc">PMC3352168</ArticleId>
            <ArticleId IdType="pubmed">19666397</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hapnes L, Willcox N, Oftedal BE, Owe JF, Gilhus NE, Meager A, Husebye ES, Wolff AS. Radioligand-binding assay reveals distinct autoantibody preferences for type I interferons in APS I and myasthenia gravis subgroups. J Clin Immunol. 2012;32:230–237. doi: 10.1007/s10875-011-9617-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10875-011-9617-4</ArticleId>
            <ArticleId IdType="pubmed">22127461</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hart IK, Sathasivam S, Sharshar T (2007) Immunosuppressive agents for myasthenia gravis. Cochrane Database Syst Rev:CD005224</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17943844</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harvey AM, Lilienthal JL, Talbot SA. Observations on the nature of myasthenia gravis. The effect of thymectomy on neuro-muscular transmission. J Clin Invest. 1942;21:579–588. doi: 10.1172/JCI101336.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI101336</ArticleId>
            <ArticleId IdType="pmc">PMC435176</ArticleId>
            <ArticleId IdType="pubmed">16694948</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heckmann JM, Rawoot A, Bateman K, Renison R, Badri M. A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis. BMC Neurol. 2011;11:97. doi: 10.1186/1471-2377-11-97.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1471-2377-11-97</ArticleId>
            <ArticleId IdType="pmc">PMC3170595</ArticleId>
            <ArticleId IdType="pubmed">21819556</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hehir MK, Burns TM, Alpers J, Conaway MR, Sawa M, Sanders DB. Mycophenolate mofetil in achr-antibody-positive myasthenia gravis: outcomes in 102 patients. Muscle Nerve. 2010;41:593–598. doi: 10.1002/mus.21640.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mus.21640</ArticleId>
            <ArticleId IdType="pubmed">20405499</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heininger K, Hendricks M, Toyka KV. Myasthenia-gravis—a new semiselective procedure to remove acetylcholine-receptor-autoantibodies from plasma. Plasma Ther Trans Technol. 1985;6:771–775.</Citation>
        </Reference>
        <Reference>
          <Citation>Hemminki K, Li X, Sundquist K. Familial risks for diseases of myoneural junction and muscle in siblings based on hospitalizations and deaths in sweden. Twin Res Hum Genet. 2006;9:573–579. doi: 10.1375/twin.9.4.573.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1375/twin.9.4.573</ArticleId>
            <ArticleId IdType="pubmed">16899165</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Henze T, Janzen RWC, Schumm F, Melms A, Sieb JP, Kohler W, Heidenreich F, Tackenberg B, Weber-Schondorfer C, Myasth ABD. Immunotherapy for myasthenia gravis and Lambert-Eaton Myasthenic Syndrome Part 2: intravenous Immunoglobulins and Apheresis Techniques. Aktuelle Neurologie. 2010;37:518–523. doi: 10.1055/s-0030-1265985.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1055/s-0030-1265985</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Herrlinger U, Weller M, Dichgans J, Melms A. Association of primary central nervous system lymphoma with long-term azathioprine therapy for myasthenia gravis? Ann Neurol. 2000;47:682–683. doi: 10.1002/1531-8249(200005)47:5&lt;682::AID-ANA24&gt;3.0.CO;2-Z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/1531-8249(200005)47:5&lt;682::AID-ANA24&gt;3.0.CO;2-Z</ArticleId>
            <ArticleId IdType="pubmed">10805346</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Higuchi O, Hamuro J, Motomura M, Yamanashi Y. Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis. Ann Neurol. 2011;69:418–422. doi: 10.1002/ana.22312.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.22312</ArticleId>
            <ArticleId IdType="pubmed">21387385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hill M, Beeson D, Moss P, Jacobson L, Bond A, Corlett L, Newsom-Davis J, Vincent A, Willcox N. Early-onset myasthenia gravis: a recurring T-cell epitope in the adult-specific acetylcholine receptor epsilon subunit presented by the susceptibility allele HLA-DR52a. Ann Neurol. 1999;45:224–231. doi: 10.1002/1531-8249(199902)45:2&lt;224::AID-ANA13&gt;3.0.CO;2-B.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/1531-8249(199902)45:2&lt;224::AID-ANA13&gt;3.0.CO;2-B</ArticleId>
            <ArticleId IdType="pubmed">9989625</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hilton-Jones D. When the patient fails to respond to treatment: myasthenia gravis. Pract Neurol. 2007;7:405–411. doi: 10.1136/jnnp.2007.134130.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp.2007.134130</ArticleId>
            <ArticleId IdType="pubmed">18024782</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med. 2001;7:365–368. doi: 10.1038/85520.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/85520</ArticleId>
            <ArticleId IdType="pubmed">11231638</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hoeltzenbein M, Weber-Schoendorfer C, Borisch C, Allignol A, Meister R, Schaefer C. Pregnancy outcome after paternal exposure to azathioprine/6-mercaptopurine. Reprod Toxicol. 2012;34:364–369. doi: 10.1016/j.reprotox.2012.05.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.reprotox.2012.05.001</ArticleId>
            <ArticleId IdType="pubmed">22609326</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hoffacker V, Schultz A, Tiesinga JJ, Gold R, Schalke B, Nix W, Kiefer R, Muller-Hermelink HK, Marx A. Thymomas alter the T-cell subset composition in the blood: a potential mechanism for thymoma-associated autoimmune disease. Blood. 2000;96:3872–3879.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11090072</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hohlfeld R, Goebels N, Engel AG. Cellular mechanisms in inflammatory myopathies. Baillieres Clin Neurol. 1993;2:617–635.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8156145</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hohlfeld R, Michels M, Heininger K, Besinger U, Toyka KV. Azathioprine toxicity during long-term immunosuppression of generalized myasthenia gravis. Neurology. 1988;38:258–261. doi: 10.1212/WNL.38.2.258.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.38.2.258</ArticleId>
            <ArticleId IdType="pubmed">3340289</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hohlfeld R, Toyka KV, Besinger UA, Gerhold B, Heininger K. Myasthenia gravis: reactivation of clinical disease and of autoimmune factors after discontinuation of long-term azathioprine. Ann Neurol. 1985;17:238–242. doi: 10.1002/ana.410170304.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.410170304</ArticleId>
            <ArticleId IdType="pubmed">3873207</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Howard JF, Jr, Barohn RJ, Cutter GR, Freimer M, Juel VC, Mozaffar T, Mellion ML, Benatar MG, Farrugia ME, Wang JJ, Malhotra SS, Kissel JT. A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis. Muscle Nerve. 2013;48:76–84. doi: 10.1002/mus.23839.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mus.23839</ArticleId>
            <ArticleId IdType="pubmed">23512355</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang H, Benoist C, Mathis D. Rituximab specifically depletes short-lived autoreactive plasma cells in a mouse model of inflammatory arthritis. Proc Natl Acad Sci USA. 2010;107:4658–4663. doi: 10.1073/pnas.1001074107.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1001074107</ArticleId>
            <ArticleId IdType="pmc">PMC2842072</ArticleId>
            <ArticleId IdType="pubmed">20176942</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huijbers MG, Zhang W, Klooster R, Niks EH, Friese MB, Straasheijm KR, Thijssen PE, Vrolijk H, Plomp JJ, Vogels P, Losen M, Van der Maarel SM, Burden SJ, Verschuuren JJ. MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4. Proc Natl Acad Sci USA. 2013;110:20783–20788. doi: 10.1073/pnas.1313944110.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1313944110</ArticleId>
            <ArticleId IdType="pmc">PMC3870730</ArticleId>
            <ArticleId IdType="pubmed">24297891</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Imbach P, Barandun S, d’Apuzzo V, Baumgartner C, Hirt A, Morell A, Rossi E, Schoni M, Vest M, Wagner HP. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet. 1981;1:1228–1231. doi: 10.1016/S0140-6736(81)92400-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(81)92400-4</ArticleId>
            <ArticleId IdType="pubmed">6112565</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Iorio R, Damato V, Alboini PE, Evoli A. Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis. J Neurol. 2015;262:1115–1119. doi: 10.1007/s00415-014-7532-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00415-014-7532-3</ArticleId>
            <ArticleId IdType="pubmed">25308632</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jaretzki A, 3rd, Penn AS, Younger DS, Wolff M, Olarte MR, Lovelace RE, Rowland LP. “Maximal” thymectomy for myasthenia gravis. Results. J Thorac Cardiovasc Surg. 1988;95:747–757.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3361927</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kerty E, Elsais A, Argov Z, Evoli A, Gilhus NE. EFNS/ENS Guidelines for the treatment of ocular myasthenia. Eur J Neurol. 2014;21:687–693. doi: 10.1111/ene.12359.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/ene.12359</ArticleId>
            <ArticleId IdType="pubmed">24471489</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kirchner T, Schalke B, Melms A, von Kugelgen T, Muller-Hermelink HK. Immunohistological patterns of non-neoplastic changes in the thymus in Myasthenia gravis. Virchows Arch B Cell Pathol Incl Mol Pathol. 1986;52:237–257. doi: 10.1007/BF02889966.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/BF02889966</ArticleId>
            <ArticleId IdType="pubmed">2879380</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kisand K, Lilic D, Casanova JL, Peterson P, Meager A, Willcox N. Mucocutaneous candidiasis and autoimmunity against cytokines in APECED and thymoma patients: clinical and pathogenetic implications. Eur J Immunol. 2011;41:1517–1527. doi: 10.1002/eji.201041253.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/eji.201041253</ArticleId>
            <ArticleId IdType="pubmed">21574164</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klooster R, Plomp JJ, Huijbers MG, Niks EH, Straasheijm KR, Detmers FJ, Hermans PW, Sleijpen K, Verrips A, Losen M, Martinez-Martinez P, De Baets MH, van der Maarel SM, Verschuuren JJ. Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice. Brain. 2012;135:1081–1101. doi: 10.1093/brain/aws025.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/aws025</ArticleId>
            <ArticleId IdType="pubmed">22396395</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kohler W, Bucka C, Klingel R. A randomized and controlled study comparing immunoadsorption and plasma exchange in myasthenic crisis. J Clin Apher. 2011;26:347–355. doi: 10.1002/jca.20317.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jca.20317</ArticleId>
            <ArticleId IdType="pubmed">22095647</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Konishi T, Yoshiyama Y, Takamori M, Saida T. Long-term treatment of generalised myasthenia gravis with FK506 (tacrolimus) J Neurol Neurosurg Psychiatry. 2005;76:448–450. doi: 10.1136/jnnp.2004.042176.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp.2004.042176</ArticleId>
            <ArticleId IdType="pmc">PMC1739570</ArticleId>
            <ArticleId IdType="pubmed">15716549</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koziolek MJ, Kitze B, Muhlhausen J, Muller GA. Immunoadsorption in steroid-refractory multiple sclerosis. Atheroscler Suppl. 2013;14:175–178. doi: 10.1016/j.atherosclerosissup.2012.10.026.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.atherosclerosissup.2012.10.026</ArticleId>
            <ArticleId IdType="pubmed">23357161</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kupersmith MJ. Ocular myasthenia gravis: treatment successes and failures in patients with long-term follow-up. J Neurol. 2009;256:1314–1320. doi: 10.1007/s00415-009-5120-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00415-009-5120-8</ArticleId>
            <ArticleId IdType="pubmed">19377863</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lauriola L, Ranelletti F, Maggiano N, Guerriero M, Punzi C, Marsili F, Bartoccioni E, Evoli A. Thymus changes in anti-MuSK-positive and -negative myasthenia gravis. Neurology. 2005;64:536–538. doi: 10.1212/01.WNL.0000150587.71497.B6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/01.WNL.0000150587.71497.B6</ArticleId>
            <ArticleId IdType="pubmed">15699390</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leite MI, Jacob S, Viegas S, Cossins J, Clover L, Morgan BP, Beeson D, Willcox N, Vincent A. IgG1 antibodies to acetylcholine receptors in ‘seronegative’ myasthenia gravis. Brain. 2008;131:1940–1952. doi: 10.1093/brain/awn092.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/awn092</ArticleId>
            <ArticleId IdType="pmc">PMC2442426</ArticleId>
            <ArticleId IdType="pubmed">18515870</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leite MI, Strobel P, Jones M, Micklem K, Moritz R, Gold R, Niks EH, Berrih-Aknin S, Scaravilli F, Canelhas A, Marx A, Newsom-Davis J, Willcox N, Vincent A. Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG. Ann Neurol. 2005;57:444–448. doi: 10.1002/ana.20386.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.20386</ArticleId>
            <ArticleId IdType="pubmed">15732104</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin PT, Martin BA, Weinacker AB, So YT. High-dose cyclophosphamide in refractory myasthenia gravis with MuSK antibodies. Muscle Nerve. 2006;33:433–435. doi: 10.1002/mus.20411.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mus.20411</ArticleId>
            <ArticleId IdType="pubmed">16116645</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lindberg C, Andersen O, Lefvert AK. Treatment of myasthenia gravis with methylprednisolone pulse: a double blind study. Acta Neurol Scand. 1998;97:370–373. doi: 10.1111/j.1600-0404.1998.tb05968.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1600-0404.1998.tb05968.x</ArticleId>
            <ArticleId IdType="pubmed">9669469</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luo J, Lindstrom J. Myasthenogenicity of the main immunogenic region and endogenous muscle nicotinic acetylcholine receptors. Autoimmunity. 2012;45:245–252. doi: 10.3109/08916934.2011.622015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/08916934.2011.622015</ArticleId>
            <ArticleId IdType="pmc">PMC3250566</ArticleId>
            <ArticleId IdType="pubmed">21950318</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maclennan CA, Vincent A, Marx A, Willcox N, Gilhus NE, Newsom-Davis J, Beeson D. Preferential expression of AChR epsilon-subunit in thymomas from patients with myasthenia gravis. J Neuroimmunol. 2008;201–202:28–32. doi: 10.1016/j.jneuroim.2008.06.016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jneuroim.2008.06.016</ArticleId>
            <ArticleId IdType="pubmed">18657869</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maniaol AH, Elsais A, Lorentzen AR, Owe JF, Viken MK, Saether H, Flam ST, Brathen G, Kampman MT, Midgard R, Christensen M, Rognerud A, Kerty E, Gilhus NE, Tallaksen CM, Lie BA, Harbo HF. Late onset myasthenia gravis is associated with HLA DRB1*15:01 in the Norwegian population. PLoS One. 2012;7:e36603. doi: 10.1371/journal.pone.0036603.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0036603</ArticleId>
            <ArticleId IdType="pmc">PMC3348874</ArticleId>
            <ArticleId IdType="pubmed">22590574</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mantegazza R, Antozzi C, Peluchetti D, Sghirlanzoni A, Cornelio F. Azathioprine as a single drug or in combination with steroids in the treatment of myasthenia gravis. J Neurol. 1988;235:449–453. doi: 10.1007/BF00314245.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/BF00314245</ArticleId>
            <ArticleId IdType="pubmed">3062134</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marx A, Pfister F, Schalke B, Saruhan-Direskeneli G, Melms A, Strobel P. The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes. Autoimmun Rev. 2013;12:875–884. doi: 10.1016/j.autrev.2013.03.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.autrev.2013.03.007</ArticleId>
            <ArticleId IdType="pubmed">23535159</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marx A, Wilisch A, Schultz A, Greiner A, Magi B, Pallini V, Schalke B, Toyka K, Nix W, Kirchner T, Muller-Hermelink HK. Expression of neurofilaments and of a titin epitope in thymic epithelial tumors. Implications for the pathogenesis of myasthenia gravis. Am J Pathol. 1996;148:1839–1850.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1861646</ArticleId>
            <ArticleId IdType="pubmed">8669470</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marx A, Willcox N, Leite MI, Chuang WY, Schalke B, Nix W, Strobel P. Thymoma and paraneoplastic myasthenia gravis. Autoimmunity. 2010;43:413–427. doi: 10.3109/08916930903555935.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/08916930903555935</ArticleId>
            <ArticleId IdType="pubmed">20380583</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Masuda T, Motomura M, Utsugisawa K, Nagane Y, Nakata R, Tokuda M, Fukuda T, Yoshimura T, Tsujihata M, Kawakami A. Antibodies against the main immunogenic region of the acetylcholine receptor correlate with disease severity in myasthenia gravis. J Neurol Neurosurg Psychiatry. 2012;83:935–940. doi: 10.1136/jnnp-2012-302705.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp-2012-302705</ArticleId>
            <ArticleId IdType="pubmed">22764264</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McConville J, Farrugia ME, Beeson D, Kishore U, Metcalfe R, Newsom-Davis J, Vincent A. Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann Neurol. 2004;55:580–584. doi: 10.1002/ana.20061.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.20061</ArticleId>
            <ArticleId IdType="pubmed">15048899</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mehndiratta MM, Pandey S, Kuntzer T (2011) Acetylcholinesterase inhibitor treatment for myasthenia gravis. Cochrane Database Syst Rev CD006986</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21328290</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mertens HG, Balzereit F, Leipert M. The treatment of severe myasthenia gravis with immunosuppressive agents. Eur Neurol. 1969;2:321–339. doi: 10.1159/000113809.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000113809</ArticleId>
            <ArticleId IdType="pubmed">4185500</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meyer DM, Herbert MA, Sobhani NC, Tavakolian P, Duncan A, Bruns M, Korngut K, Williams J, Prince SL, Huber L, Wolfe GI, Mack MJ. Comparative clinical outcomes of thymectomy for myasthenia gravis performed by extended transsternal and minimally invasive approaches. Ann Thorac Surg. 2009;87:385–391. doi: 10.1016/j.athoracsur.2008.11.040.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.athoracsur.2008.11.040</ArticleId>
            <ArticleId IdType="pubmed">19161744</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Michels M, Hohlfeld R, Hartung HP, Heininger K, Besinger UA, Toyka KV. Myasthenia gravis: discontinuation of long-term azathioprine. Ann Neurol. 1988;24:798. doi: 10.1002/ana.410240619.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.410240619</ArticleId>
            <ArticleId IdType="pubmed">3207364</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Minami N, Fujiki N, Doi S, Shima K, Niino M, Kikuchi S, Sasaki H. Five-year follow-up with low-dose tacrolimus in patients with myasthenia gravis. J Neurol Sci. 2011;300:59–62. doi: 10.1016/j.jns.2010.09.033.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jns.2010.09.033</ArticleId>
            <ArticleId IdType="pubmed">21035148</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muscle Study G  A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. Neurology. 2008;71:394–399. doi: 10.1212/01.wnl.0000312373.67493.7f.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/01.wnl.0000312373.67493.7f</ArticleId>
            <ArticleId IdType="pubmed">18434639</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nagaishi A, Yukitake M, Kuroda Y. Long-term treatment of steroid-dependent myasthenia gravis patients with low-dose tacrolimus. Intern Med. 2008;47:731–736. doi: 10.2169/internalmedicine.47.0513.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2169/internalmedicine.47.0513</ArticleId>
            <ArticleId IdType="pubmed">18421189</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nagane Y, Utsugisawa K, Obara D, Kondoh R, Terayama Y. Efficacy of low-dose FK506 in the treatment of myasthenia gravis–a randomized pilot study. Eur Neurol. 2005;53:146–150. doi: 10.1159/000085833.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000085833</ArticleId>
            <ArticleId IdType="pubmed">15900097</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Newsom-Davis J, Vincent A, Wilson SG, Ward CD, Pinching AJ, Hawkey C. Plasmapheresis for myasthenia gravis. N Engl J Med. 1978;298:456–457.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">622126</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nissenson AR. Reduction of IgG levels in myasthenia. N Engl J Med. 1977;296:819–820.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">840285</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Novellino L, Longoni M, Spinelli L, Andretta M, Cozzi M, Faillace G, Vitellaro M, De Benedetti D, Pezzuoli G. “Extended” thymectomy, without sternotomy, performed by cervicotomy and thoracoscopic technique in the treatment of myasthenia gravis. Int Surg. 1994;79:378–381.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7713713</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>O’Donovan P, Perrett CM, Zhang X, Montaner B, Xu YZ, Harwood CA, McGregor JM, Walker SL, Hanaoka F, Karran P. Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science. 2005;309:1871–1874. doi: 10.1126/science.1114233.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1114233</ArticleId>
            <ArticleId IdType="pmc">PMC2426755</ArticleId>
            <ArticleId IdType="pubmed">16166520</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Palace J, Newsom-Davis J, Lecky B. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group. Neurology. 1998;50:1778–1783. doi: 10.1212/WNL.50.6.1778.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.50.6.1778</ArticleId>
            <ArticleId IdType="pubmed">9633727</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pascuzzi RM, Coslett HB, Johns TR. Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients. Ann Neurol. 1984;15:291–298. doi: 10.1002/ana.410150316.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.410150316</ArticleId>
            <ArticleId IdType="pubmed">6721451</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pevzner A, Schoser B, Peters K, Cosma NC, Karakatsani A, Schalke B, Melms A, Kroger S. Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis. J Neurol. 2012;259:427–435. doi: 10.1007/s00415-011-6194-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00415-011-6194-7</ArticleId>
            <ArticleId IdType="pubmed">21814823</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pharmaceuticals A (2013) Safety and efficacy of eculizumab in refractory generalized myasthenia gravis (REGAIN study). ClinicalTrialsgov web-page NCT01997229</Citation>
        </Reference>
        <Reference>
          <Citation>Pinching AJ, Peters DK. Remission of myasthenia gravis following plasma-exchange. Lancet. 1976;2:1373–1376. doi: 10.1016/S0140-6736(76)91917-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(76)91917-6</ArticleId>
            <ArticleId IdType="pubmed">63848</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Poea-Guyon S, Christadoss P, Le Panse R, Guyon T, De Baets M, Wakkach A, Bidault J, Tzartos S, Berrih-Aknin S. Effects of cytokines on acetylcholine receptor expression: implications for myasthenia gravis. J Immunol. 2005;174:5941–5949. doi: 10.4049/jimmunol.174.10.5941.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.174.10.5941</ArticleId>
            <ArticleId IdType="pubmed">15879086</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pompeo E, Tacconi F, Massa R, Mineo D, Nahmias S, Mineo TC. Long-term outcome of thoracoscopic extended thymectomy for nonthymomatous myasthenia gravis. Eur J Cardiothorac Surg. 2009;36:164–169. doi: 10.1016/j.ejcts.2009.02.021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejcts.2009.02.021</ArticleId>
            <ArticleId IdType="pubmed">19339195</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ponseti JM, Azem J, Fort JM, Lopez-Cano M, Vilallonga R, Buera M, Cervera C, Armengol M. Long-term results of tacrolimus in cyclosporine- and prednisone-dependent myasthenia gravis. Neurology. 2005;64:1641–1643. doi: 10.1212/01.WNL.0000160392.32894.6D.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/01.WNL.0000160392.32894.6D</ArticleId>
            <ArticleId IdType="pubmed">15883336</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ponseti JM, Gamez J, Azem J, Lopez-Cano M, Vilallonga R, Armengol M. Tacrolimus for myasthenia gravis: a clinical study of 212 patients. Ann NY Acad Sci. 2008;1132:254–263. doi: 10.1196/annals.1405.000.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1196/annals.1405.000</ArticleId>
            <ArticleId IdType="pubmed">18096852</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Punga AR, Flink R, Askmark H, Stalberg EV. Cholinergic neuromuscular hyperactivity in patients with myasthenia gravis seropositive for MuSK antibody. Muscle Nerve. 2006;34:111–115. doi: 10.1002/mus.20515.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mus.20515</ArticleId>
            <ArticleId IdType="pubmed">16453324</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qureshi AI, Choudhry MA, Akbar MS, Mohammad Y, Chua HC, Yahia AM, Ulatowski JA, Krendel DA, Leshner RT. Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis. Neurology. 1999;52:629–632. doi: 10.1212/WNL.52.3.629.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.52.3.629</ArticleId>
            <ArticleId IdType="pubmed">10025801</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Renton AE, Pliner HA, Provenzano C, Evoli A, Ricciardi R, Nalls MA, Marangi G, Abramzon Y, Arepalli S, Chong S, Hernandez DG, Johnson JO, Bartoccioni E, Scuderi F, Maestri M, Gibbs JR, Errichiello E, Chio A, Restagno G, Sabatelli M, Macek M, Scholz SW, Corse A, Chaudhry V, Benatar M, Barohn RJ, McVey A, Pasnoor M, Dimachkie MM, Rowin J, Kissel J, Freimer M, Kaminski HJ, Sanders DB, Lipscomb B, Massey JM, Chopra M, Howard JF, Jr, Koopman WJ, Nicolle MW, Pascuzzi RM, Pestronk A, Wulf C, Florence J, Blackmore D, Soloway A, Siddiqi Z, Muppidi S, Wolfe G, Richman D, Mezei MM, Jiwa T, Oger J, Drachman DB, Traynor BJ. A genome-wide association study of myasthenia gravis. JAMA Neurol. 2015;72:396–404. doi: 10.1001/jamaneurol.2014.4103.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaneurol.2014.4103</ArticleId>
            <ArticleId IdType="pmc">PMC4856525</ArticleId>
            <ArticleId IdType="pubmed">25643325</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Robertson NP, Deans J, Compston DA. Myasthenia gravis: a population based epidemiological study in Cambridgeshire, England. J Neurol Neurosurg Psychiatry. 1998;65:492–496. doi: 10.1136/jnnp.65.4.492.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp.65.4.492</ArticleId>
            <ArticleId IdType="pmc">PMC2170309</ArticleId>
            <ArticleId IdType="pubmed">9771771</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rodriguez M, Gomez MR, Howard FM, Jr, Taylor WF. Myasthenia gravis in children: long-term follow-up. Ann Neurol. 1983;13:504–510. doi: 10.1002/ana.410130506.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.410130506</ArticleId>
            <ArticleId IdType="pubmed">6870202</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Romi F, Aarli JA, Gilhus NE. Myasthenia gravis patients with ryanodine receptor antibodies have distinctive clinical features. Eur J Neurol. 2007;14:617–620. doi: 10.1111/j.1468-1331.2007.01785.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1468-1331.2007.01785.x</ArticleId>
            <ArticleId IdType="pubmed">17539937</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Romi F, Bo L, Skeie GO, Myking A, Aarli JA, Gilhus NE. Titin and ryanodine receptor epitopes are expressed in cortical thymoma along with costimulatory molecules. J Neuroimmunol. 2002;128:82–89. doi: 10.1016/S0165-5728(02)00145-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0165-5728(02)00145-5</ArticleId>
            <ArticleId IdType="pubmed">12098514</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roxanis I, Micklem K, McConville J, Newsom-Davis J, Willcox N. Thymic myoid cells and germinal center formation in myasthenia gravis; possible roles in pathogenesis. J Neuroimmunol. 2002;125:185–197. doi: 10.1016/S0165-5728(02)00038-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0165-5728(02)00038-3</ArticleId>
            <ArticleId IdType="pubmed">11960656</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ruckert JC, Gellert K, Muller JM. Operative technique for thoracoscopic thymectomy. Surg Endosc. 1999;13:943–946. doi: 10.1007/s004649901142.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s004649901142</ArticleId>
            <ArticleId IdType="pubmed">10449861</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sabbagh MN, Garza JS, Patten B. Thoracoscopic thymectomy in patients with myasthenia gravis. Muscle Nerve. 1995;18:1475–1477. doi: 10.1002/mus.880181220.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mus.880181220</ArticleId>
            <ArticleId IdType="pubmed">7477073</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Samtleben W, Besinger UA, Toyka KV, Fateh-Moghadam A, Brehm G, Gurland HJ. Plasma-separation in myasthenia gravis: a new method of rapid plasma exchange. Klin Wochenschr. 1980;58:47–49. doi: 10.1007/BF01477144.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/BF01477144</ArticleId>
            <ArticleId IdType="pubmed">6154830</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sanders DB, El-Salem K, Massey JM, McConville J, Vincent A. Clinical aspects of MuSK antibody positive seronegative MG. Neurology. 2003;60:1978–1980. doi: 10.1212/01.WNL.0000065882.63904.53.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/01.WNL.0000065882.63904.53</ArticleId>
            <ArticleId IdType="pubmed">12821744</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sanders DB, Hart IK, Mantegazza R, Shukla SS, Siddiqi ZA, De Baets MH, Melms A, Nicolle MW, Solomons N, Richman DP. An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology. 2008;71:400–406. doi: 10.1212/01.wnl.0000312374.95186.cc.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/01.wnl.0000312374.95186.cc</ArticleId>
            <ArticleId IdType="pubmed">18434638</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sanders DB, Howard JF, Jr, Johns TR. Single-fiber electromyography in myasthenia gravis. Neurology. 1979;29:68–76. doi: 10.1212/WNL.29.1.68.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.29.1.68</ArticleId>
            <ArticleId IdType="pubmed">218146</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sanes JR, Lichtman JW. Induction, assembly, maturation and maintenance of a postsynaptic apparatus. Nat Rev Neurosci. 2001;2:791–805. doi: 10.1038/35097557.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/35097557</ArticleId>
            <ArticleId IdType="pubmed">11715056</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Savino W, Manganella G, Verley JM, Wolff A, Berrih S, Levasseur P, Binet JP, Dardenne M, Bach JF. Thymoma epithelial cells secrete thymic hormone but do not express class II antigens of the major histocompatibility complex. J Clin Invest. 1985;76:1140–1146. doi: 10.1172/JCI112069.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI112069</ArticleId>
            <ArticleId IdType="pmc">PMC424007</ArticleId>
            <ArticleId IdType="pubmed">2413072</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schluep M, Willcox N, Vincent A, Dhoot GK, Newsom-Davis J. Acetylcholine receptors in human thymic myoid cells in situ: an immunohistological study. Ann Neurol. 1987;22:212–222. doi: 10.1002/ana.410220205.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.410220205</ArticleId>
            <ArticleId IdType="pubmed">3662452</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schneider-Gold C, Gajdos P, Toyka KV, Hohlfeld RR (2005) Corticosteroids for myasthenia gravis. Cochrane Database Syst Rev:CD002828</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15846640</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schroder A, Linker RA, Gold R. Plasmapheresis for neurological disorders. Expert Rev Neurother. 2009;9:1331–1339. doi: 10.1586/ern.09.81.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1586/ern.09.81</ArticleId>
            <ArticleId IdType="pubmed">19769448</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seldin MF, Alkhairy OK, Lee AT, Lamb JA, Sussman J, Pirskanen-Matell R, Piehl F, Verschuuren JJ, Kostera-Pruszczyk A, Szczudlik P, McKee D, Maniaol AH, Harbo HF, Lie BA, Melms A, Garchon HJ, Willcox N, Gregersen PK, Hammarstrom L (2015) Genome-wide Association Study of Late-Onset Myasthenia Gravis: Confirmation of TNFRSF11A, and Identification of ZBTB10 and Three Distinct HLA Associations. Mol Med</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4749491</ArticleId>
            <ArticleId IdType="pubmed">26562150</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seybold ME. Thymectomy in childhood myasthenia gravis. Ann N Y Acad Sci. 1998;841:731–741. doi: 10.1111/j.1749-6632.1998.tb11010.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1749-6632.1998.tb11010.x</ArticleId>
            <ArticleId IdType="pubmed">9668322</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seybold ME, Drachman DB. Gradually increasing doses of prednisone in myasthenia gravis. Reducing the hazards of treatment. N Engl J Med. 1974;290:81–84. doi: 10.1056/NEJM197401102900204.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJM197401102900204</ArticleId>
            <ArticleId IdType="pubmed">4808454</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shen C, Lu Y, Zhang B, Figueiredo D, Bean J, Jung J, Wu H, Barik A, Yin DM, Xiong WC, Mei L. Antibodies against low-density lipoprotein receptor-related protein 4 induce myasthenia gravis. J Clin Invest. 2013;123:5190–5202. doi: 10.1172/JCI66039.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI66039</ArticleId>
            <ArticleId IdType="pmc">PMC3859418</ArticleId>
            <ArticleId IdType="pubmed">24200689</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shigemoto K, Kubo S, Maruyama N, Hato N, Yamada H, Jie C, Kobayashi N, Mominoki K, Abe Y, Ueda N, Matsuda S. Induction of myasthenia by immunization against muscle-specific kinase. J Clin Invest. 2006;116:1016–1024. doi: 10.1172/JCI21545.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI21545</ArticleId>
            <ArticleId IdType="pmc">PMC1409737</ArticleId>
            <ArticleId IdType="pubmed">16557298</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shiraishi H, Motomura M, Yoshimura T, Fukudome T, Fukuda T, Nakao Y, Tsujihata M, Vincent A, Eguchi K. Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis. Ann Neurol. 2005;57:289–293. doi: 10.1002/ana.20341.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.20341</ArticleId>
            <ArticleId IdType="pubmed">15668981</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Siara J, Rudel R, Marx A. Absence of acetylcholine-induced current in epithelial cells from thymus glands and thymomas of myasthenia gravis patients. Neurology. 1991;41:128–131. doi: 10.1212/WNL.41.1.128.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.41.1.128</ArticleId>
            <ArticleId IdType="pubmed">1702196</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Skeie GO, Apostolski S, Evoli A, Gilhus NE, Illa I, Harms L, Hilton-Jones D, Melms A, Verschuuren J, Horge HW, European Federation of Neurological S  Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol. 2010;17:893–902. doi: 10.1111/j.1468-1331.2010.03019.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1468-1331.2010.03019.x</ArticleId>
            <ArticleId IdType="pubmed">20402760</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Slesak G, Melms A, Fea Gerneth.  Late-onset myasthenia gravis– follow-up of 113 patients diagnosed after age 60. In: Richman DP, editor. Myasthenia Gravis and Related Diseases: Disorders of the Neuromuscular Junction. New York: Ann NY Acad Sci; 1998. pp. 777–780.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9668329</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sommer N, Sigg B, Melms A, Weller M, Schepelmann K, Herzau V, Dichgans J. Ocular myasthenia gravis: response to long-term immunosuppressive treatment. J Neurol Neurosurg Psychiatry. 1997;62:156–162. doi: 10.1136/jnnp.62.2.156.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp.62.2.156</ArticleId>
            <ArticleId IdType="pmc">PMC486727</ArticleId>
            <ArticleId IdType="pubmed">9048716</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stangel M, Gold R. Administration of intravenous immunoglobulins in neurology. An evidence-based consensus: update 2010. Nervenarzt. 2011;82:415–416. doi: 10.1007/s00115-010-3059-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00115-010-3059-8</ArticleId>
            <ArticleId IdType="pubmed">20577707</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Strobel P, Bauer A, Puppe B, Kraushaar T, Krein A, Toyka K, Gold R, Semik M, Kiefer R, Nix W, Schalke B, Muller-Hermelink HK, Marx A. Tumor recurrence and survival in patients treated for thymomas and thymic squamous cell carcinomas: a retrospective analysis. J Clin Oncol. 2004;22:1501–1509. doi: 10.1200/JCO.2004.10.113.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2004.10.113</ArticleId>
            <ArticleId IdType="pubmed">15084623</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Strobel P, Chuang WY, Chuvpilo S, Zettl A, Katzenberger T, Kalbacher H, Rieckmann P, Nix W, Schalke B, Gold R, Muller-Hermelink HK, Peterson P, Marx A. Common cellular and diverse genetic basis of thymoma-associated myasthenia gravis: role of MHC class II and AIRE genes and genetic polymorphisms. Ann NY Acad Sci. 2008;1132:143–156. doi: 10.1196/annals.1405.018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1196/annals.1405.018</ArticleId>
            <ArticleId IdType="pubmed">18567864</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Strobel P, Helmreich M, Menioudakis G, Lewin SR, Rudiger T, Bauer A, Hoffacker V, Gold R, Nix W, Schalke B, Elert O, Semik M, Muller-Hermelink HK, Marx A. Paraneoplastic myasthenia gravis correlates with generation of mature naive CD4(+) T cells in thymomas. Blood. 2002;100:159–166. doi: 10.1182/blood.V100.1.159.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood.V100.1.159</ArticleId>
            <ArticleId IdType="pubmed">12070022</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Strobel P, Moritz R, Leite MI, Willcox N, Chuang WY, Gold R, Nix W, Schalke B, Kiefer R, Muller-Hermelink HK, Jaretzki Iii A, Newsom-Davis J, Marx A. The ageing and myasthenic thymus: a morphometric study validating a standard procedure in the histological workup of thymic specimens. J Neuroimmunol. 2008;201–202:64–73. doi: 10.1016/j.jneuroim.2008.06.017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jneuroim.2008.06.017</ArticleId>
            <ArticleId IdType="pubmed">18657325</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Strobel P, Murumagi A, Klein R, Luster M, Lahti M, Krohn K, Schalke B, Nix W, Gold R, Rieckmann P, Toyka K, Burek C, Rosenwald A, Muller-Hermelink HK, Pujoll-Borrell R, Meager A, Willcox N, Peterson P, Marx A. Deficiency of the autoimmune regulator AIRE in thymomas is insufficient to elicit autoimmune polyendocrinopathy syndrome type 1 (APS-1) J Pathol. 2007;211:563–571. doi: 10.1002/path.2141.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/path.2141</ArticleId>
            <ArticleId IdType="pubmed">17334980</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Strobel P, Rosenwald A, Beyersdorf N, Kerkau T, Elert O, Murumagi A, Sillanpaa N, Peterson P, Hummel V, Rieckmann P, Burek C, Schalke B, Nix W, Kiefer R, Muller-Hermelink HK, Marx A. Selective loss of regulatory T cells in thymomas. Ann Neurol. 2004;56:901–904. doi: 10.1002/ana.20340.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.20340</ArticleId>
            <ArticleId IdType="pubmed">15562414</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Strober J, Cowan MJ, Horn BN. Allogeneic hematopoietic cell transplantation for refractory myasthenia gravis. Arch Neurol. 2009;66:659–661. doi: 10.1001/archneurol.2009.28.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archneurol.2009.28</ArticleId>
            <ArticleId IdType="pubmed">19433668</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tackenberg B, Hemmer B, Oertel WH, Sommer N. Immunosuppressive treatment of ocular myasthenia gravis. BioDrugs. 2001;15:369–378. doi: 10.2165/00063030-200115060-00003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2165/00063030-200115060-00003</ArticleId>
            <ArticleId IdType="pubmed">11520248</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tackenberg B, Nitschke M, Willcox N, Ziegler A, Nessler S, Schumm F, Oertel WH, Hemmer B, Sommer N. CD45 isoform expression in autoimmune myasthenia gravis. Autoimmunity. 2003;36:117–121. doi: 10.1080/0891693031000084369.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/0891693031000084369</ArticleId>
            <ArticleId IdType="pubmed">12820694</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tackenberg B, Schlegel K, Happel M, Eienbroker C, Gellert K, Oertel WH, Meager A, Willcox N, Sommer N. Expanded TCR Vbeta subsets of CD8(+) T-cells in late-onset myasthenia gravis: novel parallels with thymoma patients. J Neuroimmunol. 2009;216:85–91. doi: 10.1016/j.jneuroim.2009.08.018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jneuroim.2009.08.018</ArticleId>
            <ArticleId IdType="pubmed">19781791</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tada M, Shimohata T, Tada M, Oyake M, Igarashi S, Onodera O, Naruse S, Tanaka K, Tsuji S, Nishizawa M. Long-term therapeutic efficacy and safety of low-dose tacrolimus (FK506) for myasthenia gravis. J Neurol Sci. 2006;247:17–20. doi: 10.1016/j.jns.2006.03.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jns.2006.03.010</ArticleId>
            <ArticleId IdType="pubmed">16631797</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thiruppathi M, Rowin J, Ganesh B, Sheng JR, Prabhakar BS, Meriggioli MN. Impaired regulatory function in circulating CD4(+)CD25(high)CD127(low/−) T cells in patients with myasthenia gravis. Clin Immunol. 2012;145:209–223. doi: 10.1016/j.clim.2012.09.012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.clim.2012.09.012</ArticleId>
            <ArticleId IdType="pmc">PMC3501560</ArticleId>
            <ArticleId IdType="pubmed">23110942</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tindall RS, Phillips JT, Rollins JA, Wells L, Hall K. A clinical therapeutic trial of cyclosporine in myasthenia gravis. Ann NY Acad Sci. 1993;681:539–551. doi: 10.1111/j.1749-6632.1993.tb22937.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1749-6632.1993.tb22937.x</ArticleId>
            <ArticleId IdType="pubmed">8357194</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Toyka KV, Brachman DB, Pestronk A, Kao I. Myasthenia gravis: passive transfer from man to mouse. Science. 1975;190:397–399. doi: 10.1126/science.1179220.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1179220</ArticleId>
            <ArticleId IdType="pubmed">1179220</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Toyka KV, Drachman DB, Griffin DE, Pestronk A, Winkelstein JA, Fishbeck KH, Kao I. Myasthenia gravis. Study of humoral immune mechanisms by passive transfer to mice. N Engl J Med. 1977;296:125–131. doi: 10.1056/NEJM197701202960301.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJM197701202960301</ArticleId>
            <ArticleId IdType="pubmed">831074</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tracy MM, McRae W, Millichap JG. Graded response to thymectomy in children with myasthenia gravis. J Child Neurol. 2009;24:454–459. doi: 10.1177/0883073808325653.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/0883073808325653</ArticleId>
            <ArticleId IdType="pubmed">19339286</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG (2015) WHO classification of tumours of the lung, pleura, thymus and heart. IARC Press 4th ed</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26291007</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trontelj JV, Stalberg E. Single fiber electromyography in studies of neuromuscular function. Adv Exp Med Biol. 1995;384:109–119. doi: 10.1007/978-1-4899-1016-5_9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/978-1-4899-1016-5_9</ArticleId>
            <ArticleId IdType="pubmed">8585443</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tumani H. Corticosteroids and plasma exchange in multiple sclerosis. J Neurol. 2008;255(Suppl 6):36–42. doi: 10.1007/s00415-008-6007-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00415-008-6007-9</ArticleId>
            <ArticleId IdType="pubmed">19300958</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tzartos SJ, Lindstrom JM. Monoclonal antibodies used to probe acetylcholine receptor structure: localization of the main immunogenic region and detection of similarities between subunits. Proc Natl Acad Sci USA. 1980;77:755–759. doi: 10.1073/pnas.77.2.755.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.77.2.755</ArticleId>
            <ArticleId IdType="pmc">PMC348359</ArticleId>
            <ArticleId IdType="pubmed">6153804</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Van de Velde RL, Friedman NB. Thymic myoid cells and myasthenia gravis. Am J Pathol. 1970;59:347–368.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2032872</ArticleId>
            <ArticleId IdType="pubmed">4986259</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vernino S, Salomao DR, Habermann TM, O’Neill BP. Primary CNS lymphoma complicating treatment of myasthenia gravis with mycophenolate mofetil. Neurology. 2005;65:639–641. doi: 10.1212/01.wnl.0000173031.56429.04.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/01.wnl.0000173031.56429.04</ArticleId>
            <ArticleId IdType="pubmed">16116136</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vincent A, Jacobson L, Shillito P. Response to human acetylcholine receptor alpha 138–199: determinant spreading initiates autoimmunity to self-antigen in rabbits. Immunol Lett. 1994;39:269–275. doi: 10.1016/0165-2478(94)90168-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0165-2478(94)90168-6</ArticleId>
            <ArticleId IdType="pubmed">7518419</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wakkach A, Poea S, Chastre E, Gespach C, Lecerf F, De La Porte S, Tzartos S, Coulombe A, Berrih-Aknin S. Establishment of a human thymic myoid cell line. Phenotypic and functional characteristics. Am J Pathol. 1999;155:1229–1240. doi: 10.1016/S0002-9440(10)65225-X.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0002-9440(10)65225-X</ArticleId>
            <ArticleId IdType="pmc">PMC1867031</ArticleId>
            <ArticleId IdType="pubmed">10514405</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Willcox N, Leite MI, Kadota Y, Jones M, Meager A, Subrahmanyam P, Dasgupta B, Morgan BP, Vincent A. Autoimmunizing mechanisms in thymoma and thymus. Ann NY Acad Sci. 2008;1132:163–173. doi: 10.1196/annals.1405.021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1196/annals.1405.021</ArticleId>
            <ArticleId IdType="pubmed">18567866</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Willcox N, Schluep M, Ritter MA, Schuurman HJ, Newsom-Davis J, Christensson B. Myasthenic and nonmyasthenic thymoma. An expansion of a minor cortical epithelial cell subset? Am J Pathol. 1987;127:447–460.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1899778</ArticleId>
            <ArticleId IdType="pubmed">2438939</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Witte AS, Cornblath DR, Parry GJ, Lisak RP, Schatz NJ. Azathioprine in the treatment of myasthenia gravis. Ann Neurol. 1984;15:602–605. doi: 10.1002/ana.410150615.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.410150615</ArticleId>
            <ArticleId IdType="pubmed">6742794</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Witte AS, Cornblath DR, Schatz NJ, Lisak RP. Monitoring azathioprine therapy in myasthenia gravis. Neurology. 1986;36:1533–1534. doi: 10.1212/WNL.36.11.1533.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.36.11.1533</ArticleId>
            <ArticleId IdType="pubmed">3762975</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wolfe GI, Kaminski HJ, Jaretzki A, 3rd, Swan A, Newsom-Davis J. Development of a thymectomy trial in nonthymomatous myasthenia gravis patients receiving immunosuppressive therapy. Ann NY Acad Sci. 2003;998:473–480. doi: 10.1196/annals.1254.061.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1196/annals.1254.061</ArticleId>
            <ArticleId IdType="pubmed">14592916</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yeh JH, Chiu HC. Comparison between double-filtration plasmapheresis and immunoadsorption plasmapheresis in the treatment of patients with myasthenia gravis. J Neurol. 2000;247:510–513. doi: 10.1007/s004150070149.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s004150070149</ArticleId>
            <ArticleId IdType="pubmed">10993491</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yim AP, Kay RL, Ho JK. Video-assisted thoracoscopic thymectomy for myasthenia gravis. Chest. 1995;108:1440–1443. doi: 10.1378/chest.108.5.1440.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1378/chest.108.5.1440</ArticleId>
            <ArticleId IdType="pubmed">7587454</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yoshikawa H, Kiuchi T, Saida T, Takamori M. Randomised, double-blind, placebo-controlled study of tacrolimus in myasthenia gravis. J Neurol Neurosurg Psychiatry. 2011;82:970–977. doi: 10.1136/jnnp-2011-300148.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp-2011-300148</ArticleId>
            <ArticleId IdType="pubmed">21784757</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zeitler H, Ulrich-Merzenich G, Hoffmann L, Kornblum C, Schmidt S, Vetter H, Walger P. Long-term effects of a multimodal approach including immunoadsorption for the treatment of myasthenic crisis. Artif Organs. 2006;30:597–605. doi: 10.1111/j.1525-1594.2006.00268.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1525-1594.2006.00268.x</ArticleId>
            <ArticleId IdType="pubmed">16911313</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang B, Shen C, Bealmear B, Ragheb S, Xiong WC, Lewis RA, Lisak RP, Mei L. Autoantibodies to agrin in myasthenia gravis patients. PLoS One. 2014;9:e91816. doi: 10.1371/journal.pone.0091816.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0091816</ArticleId>
            <ArticleId IdType="pmc">PMC3954737</ArticleId>
            <ArticleId IdType="pubmed">24632822</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang B, Tzartos JS, Belimezi M, Ragheb S, Bealmear B, Lewis RA, Xiong WC, Lisak RP, Tzartos SJ, Mei L. Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis. Arch Neurol. 2012;69:445–451. doi: 10.1001/archneurol.2011.2393.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archneurol.2011.2393</ArticleId>
            <ArticleId IdType="pubmed">22158716</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou L, McConville J, Chaudhry V, Adams RN, Skolasky RL, Vincent A, Drachman DB. Clinical comparison of muscle-specific tyrosine kinase (MuSK) antibody-positive and -negative myasthenic patients. Muscle Nerve. 2004;30:55–60. doi: 10.1002/mus.20069.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mus.20069</ArticleId>
            <ArticleId IdType="pubmed">15221879</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zinman L, Ng E, Bril V. IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. Neurology. 2007;68:837–841. doi: 10.1212/01.wnl.0000256698.69121.45.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/01.wnl.0000256698.69121.45</ArticleId>
            <ArticleId IdType="pubmed">17353471</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zisimopoulou P, Evangelakou P, Tzartos J, Lazaridis K, Zouvelou V, Mantegazza R, Antozzi C, Andreetta F, Evoli A, Deymeer F, Saruhan-Direskeneli G, Durmus H, Brenner T, Vaknin A, Berrih-Aknin S, Frenkian Cuvelier M, Stojkovic T, DeBaets M, Losen M, Martinez-Martinez P, Kleopa KA, Zamba-Papanicolaou E, Kyriakides T, Kostera-Pruszczyk A, Szczudlik P, Szyluk B, Lavrnic D, Basta I, Peric S, Tallaksen C, Maniaol A, Tzartos SJ. A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis. J Autoimmun. 2014;52:139–145. doi: 10.1016/j.jaut.2013.12.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaut.2013.12.004</ArticleId>
            <ArticleId IdType="pubmed">24373505</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
